A Multicenter, Randomized, Double-Blind, Parallel-Group Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy Compared With Imiglucerase in Patients With Type I Gaucher Disease
收藏DataCite Commons2025-06-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007249/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme
glucocerebrosidase (GCB). Due to the deficiency of functional GCB, glucocerebroside
accumulates within macrophages leading to cellular engorgement, organomegaly, and organ
system dysfunction. The purpose of this non-inferiority study is to evaluate the efficacy and
safety of GA-GCB (velaglucerase alfa) administered every other week in comparison to
imiglucerase in treatment naive patients with type 1 Gaucher disease.
提供机构：
Vivli
创建时间：
2021-07-01
